

Mid-term TBVAC2020 Key achievements - 2017

Discovery to diversifying the pipeline:

- 7 antigen based vaccination approaches under investigation
- 5 live vaccines ready for testing
- 8 immunization strategies developed
- 3 delivery systems under investigation

Discovery resulting in innovation:

- 4 novel cutting-edge technologies (to identify antigens and epitopes)
- 3 novel pre-clinical models established
- A biosignature and biomarker database developed and operational

Contribution to the Global TB vaccine pipeline

Discovery	Preclinical	Phase I	Phase IIa	Phase IIb	Phase II
IMBIOVAC1.02 (Novartis) 23 candidate antigens, 10 epitopes, 10 immunization strategies	Contribution vaccine prime boost (GSK, TBV)	MINDA (GSK, Novartis) University of Oxford, TBV	IMVING (VBI, TBV, Novartis, TBV)	IMV2 (Novartis, TBV, Astra, TBV)	M-1000 (Astra, TBV)
IMBIOVAC1.03 (Novartis)	IMBIOVAC1.04 (Novartis)	IMBIOVAC1.05 (Novartis)	IMBIOVAC1.06 (Novartis)	IMBIOVAC1.07 (Novartis)	IMBIOVAC1.08 (Novartis)
IMBIOVAC1.09 (Novartis)	IMBIOVAC1.10 (Novartis)	IMBIOVAC1.11 (Novartis)	IMBIOVAC1.12 (Novartis)	IMBIOVAC1.13 (Novartis)	IMBIOVAC1.14 (Novartis)
IMBIOVAC1.15 (Novartis)	IMBIOVAC1.16 (Novartis)	IMBIOVAC1.17 (Novartis)	IMBIOVAC1.18 (Novartis)	IMBIOVAC1.19 (Novartis)	IMBIOVAC1.20 (Novartis)
IMBIOVAC1.21 (Novartis)	IMBIOVAC1.22 (Novartis)	IMBIOVAC1.23 (Novartis)	IMBIOVAC1.24 (Novartis)	IMBIOVAC1.25 (Novartis)	IMBIOVAC1.26 (Novartis)
IMBIOVAC1.27 (Novartis)	IMBIOVAC1.28 (Novartis)	IMBIOVAC1.29 (Novartis)	IMBIOVAC1.30 (Novartis)	IMBIOVAC1.31 (Novartis)	IMBIOVAC1.32 (Novartis)
IMBIOVAC1.33 (Novartis)	IMBIOVAC1.34 (Novartis)	IMBIOVAC1.35 (Novartis)	IMBIOVAC1.36 (Novartis)	IMBIOVAC1.37 (Novartis)	IMBIOVAC1.38 (Novartis)
IMBIOVAC1.39 (Novartis)	IMBIOVAC1.40 (Novartis)	IMBIOVAC1.41 (Novartis)	IMBIOVAC1.42 (Novartis)	IMBIOVAC1.43 (Novartis)	IMBIOVAC1.44 (Novartis)
IMBIOVAC1.45 (Novartis)	IMBIOVAC1.46 (Novartis)	IMBIOVAC1.47 (Novartis)	IMBIOVAC1.48 (Novartis)	IMBIOVAC1.49 (Novartis)	IMBIOVAC1.50 (Novartis)

Pre-/ early clinical development:

- To support development and for rational selection:
- 51 new tests of safety, immunogenicity and/or efficacy conducted
 - 5 candidates supported for product development

Pre-/ early clinical development:

- Rational selection:
- 6 standardized preclinical H-to-H models available for candidate comparison
 - 21 candidates selected for H-to-H comparison
 - 6 candidates deselected/down selected
 - 1 candidate selected for a phase 1 trial

Knowledge sharing:

- 63 publications in 26 journals
- Presentations at >70 scientific meetings

Knowledge exchange:

- 3 annual meetings
- Over 160 participant attended the annual meeting

Contribution to EU scientific excellence



TBVAC2020 consortium:

- 42 institutions from 15 countries
- 2 Industry partners and 3 SMEs linked with TBVAC2020 consortium partners.
- In total 248 individuals (136 females, 112 males) involved TBVAC2020 project activities.
- TBVI coordinator of the project